EP Patent

EP3321270C0 — SODIUM(2R,5S,13AR)-7,9-DIOXO-10-((2,4,6-TRIFLUOROBENZYL)CARBAMOYL)-2,3,4,5,7,9,13,13A-OCTAHYDRO-2,5-METHANOPYRIDO[1',2':4,5]PYRAZINE [2, 1-B]OXAZEPINE-8-OLATE

Assigned to Gilead Sciences Inc · Expires 2024-12-04 · 1y expired

What this patent protects

Patent listed against bictegravir-sodium.

Drugs covered by this patent

bictegravir-sodium (BICTEGRAVIR SODIUM)

Patent Metadata

Patent number: EP3321270C0
Jurisdiction: EP
Classification: —
Expires: 2024-12-04
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.